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Introduction
The current population is living longer than ever before as a result of improved health care 
services; therefore, the size of the ageing population is increasing [1]. Dementia is emerging as one 
of the main conditions affecting the elderly population. According to the WHO report, in 2010, 
there were approximately 35.6 million people suffering from dementia worldwide. This figure 
continues to rise, doubling approximately every 20 years and it is estimated that this will soon rise 
to 65.7 million by 2030, and further to 115.4 million by 2050. Current incidence shows an individual 
is diagnosed with dementia every four seconds. This has substantial socioeconomic and financial 
implications on people globally and the societal costs associated with disease were estimated at US$ 
605 billion in 2010 [2].
Alzheimer’s Disease (AD) is the most common of dementia, closely followed by nonspecific 
degenerative dementia, whereas vascular dementia, dementia from Parkinson’s disease and 
mixed dementia are observed less frequently [3]. Dementia has various impacts on the individual 
including a progressive loss of memory and deterioration in cognitive and behavioural functions 
[4]. Behavioural and psychological symptoms of dementia (BPSD) are commonly seen as the illness 
progresses. The disorder can be organized into four main groups: mood disorders, sleep disorders, 
psychotic symptoms and agitation [5]. Approximately 50-90% of people with dementia experience 
at least one symptom of behavioural disturbances at any one point [4,8-9]. Hence, this disorder has 
shown a significant impact on the quality of life of these individuals, their families and caregivers 
[10].
Both non-pharmacological and pharmacological interventions are used for the management of 
BPSD. In general, the non-pharmacological approach is recommended as the first-line intervention. 
The pharmacological approach should be initiated when the non-pharmacological approaches are 
unsuccessful; however, integrated interventions are advised for better management of dementia [11]. 
The management of patients with BPSD is quite complex and the most common pharmacological 
agents used include: antipsychotics, antidepressants, mood stabilizers, benzodiazepines and 
cognitive enhancers [1,11-12]. However, antipsychotic drugs are prescribed more frequently for 
BPSD as compared to other drug classes [1]. 
In 2005, U.S. Food and Drug Administration (US-FDA) launched an awareness campaign in 
regard to the adverse effects of Atypical Antipsychotics1 (AAs) for the elderly BPSD population due 
to a 1.7% increase in the incidence of all-cause mortality risk [13]. Three years later, the FDA extended 
the warning to also include typical antipsychotics2 [14]. Consequently, the trend of prescribing 
antipsychotics dropped from 2.3% in 2003 to 1.8% in 2011; however, the rate of prescribing AAs is 
reversing with an escalation from 0.37% to 0.64% [15]. Although there is controversial evidence in 
their effectiveness and safety, AAs are routinely prescribed for BPSD treatment [16]. 
Currently, there are no definitive treatments approved by the US-FDA for people with BPSD 
[5]. In addition, the treatment guidelines for BPSD remain controversial. Physicians have widely 
prescribed both typical and atypical antipsychotics drugs as the first-line interventions. Despite the 
high costs, AAs are more likely to be used for the treatment of BPSD, relative to typical drugs due to 
the increased efficacy and reduced side effect which includes preventing Extra Pyramidal Symptoms 
(EPS) in the geriatric population [1,4].
In clinical practice, the physicians have a variety of drug prescriptions and care plans in place 
for patients with BPSD. As a result, it is extremely important to determine the cost-effectiveness of 
AAs for use in BPSD as it not only affects the quality of life of patients and caregivers but also places 
additional burden on the health care system. Identifying which drug or combination of drugs is 
“most cost-effective” will indicate the most appropriate intervention and provide useful information 
on treatment plans for patients, caregivers, relatives and physicians. Also, the optimal treatment 
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pathway should prevent any severe impact on the quality of life of 
both patients and caregivers. The aim of this study is to explore and 
review the cost and effectiveness of using atypical antipsychotics 
in BPSD. Therefore it is pertinent that future research integrates 
pharmacological, epidemiological and health economic evaluation 
techniques in order to find most cost-effective treatment of BPSD for 
dementia patients.
Progression of Dementia
Dementia is a progressive brain disease associated with 
impairments in normal brain functioning. This includes cognitive, 
personality, and intellectual dysfunctions. It affects memory, 
thinking, language, learning ability, calculation, comprehension, 
judgment, and orientation. Thus, deterioration of the brain in this 
way can have a significant impact on people living with the condition, 
as well as on the society as a whole [2,17-19]. Alzheimer’s Disease 
(AD) is the most common type of dementia, accounting for 50-70% 
of cases. Vascular Dementia (VaD), Dementia With Lewy Bodies 
(DLB), and Front Temporal Dementia (FTD) are also paramount 
categories of the disorder accounting for 20%, 10% and 2% of cases, 
respectively [9,17-18]. According to the World Health Organization, 
dementia can be classified into three stages: (i) the early stage (first or 
second year of the condition); (ii) the middle stage (second to fourth 
or fifth year with condition); and finally (iii) the late stage (fifth year 
and beyond) [2].
Behavioural and Psychological Symptoms of Dementia 
(BPSD)
Behavioural and psychological symptoms are commonly observed 
in the disease. These include neuropsychiatric and non-cognitive 
symptoms as well as behavioural disturbances [9,20]. Diagnosis 
of BPSD has no specific approach; therefore, clinical magnitude is 
more subjective than objective in patients with dementia. The clinical 
symptoms of BPSD present themselves as: agitation, apathy, anxiety, 
depression, delusion, hallucination, disinhibition, aberrant motor 
behavior, elation, irritability, and sleep and appetite changes [9,20-
21]. BPSD tends to be more prevalent in the late stages of dementia. 
This results in distress among caregivers and patients, long term 
hospitalization, drug abuse, and other healthcare costs [21]. This 
alongside the decline in patients’ and caregivers’ quality of life makes 
BPSD a complex condition to manage.
Prevalence and Economic Impact of Dementia
Dementia is a worldwide problem resulting from the rapid 
increase in size of the over 60 population which is estimated to reach 
2 billion by 2050 [2]. It is predicted that nearly 7% (135 million) of this 
population will be diagnosed with dementia by 2050 (Figure 1) [22]. 
This will have significant social and economic impacts worldwide. 
There are three different types of costs associated with dementia care, 
namely informal care, direct social costs, and direct medical costs 
(Figure 2) and their proportion tends to vary according to the size and 
wealth of the country. In high income countries, the cost of informal 
care (provided by unpaid family members and friends) and direct 
social care both exceeded more than 40% of the total costs whereas, 
the direct medical cost was far less. Conversely, in lower-middle and 
low income countries there were significant greater costs related to 
informal care but not of direct social care. This shows that the burden 
of dementia management and care components impact on different 
socio-economic costs across the world including informal care wages 
and health and social care delivery costs.
Management of Behavioural and Psychological 
Symptoms of Dementia
People with dementia may experience BPSD at any point during 
its progression. This is associated with poorer health and quality 
of life outcomes for both patients and caregivers. As previously 
highlighted, the guidelines for the management of BPSD include both 
non-pharmacological and pharmacological approaches.
Non-Pharmacological Approach
The non-pharmacological approach is recommended as a 
first-line management for BPSD [9,11-12,23-25]. Treatment for 
behavioural disorders is administered after symptoms are reported. 
The most common approaches are environmental design, music 
therapy, light therapy, and educating caregivers on behavioural 
disturbances [9,23]. These also include the stimulation/activities and 
simple tasks for apathy [26-27]. Furthermore, Fujii et al. suggested 
that behavioural and psychological symptoms of caregivers (BPSC) 
which generally occurs as a result of BPSD in patients can impact on 
the relationship and emotions of the patient [28]. 
Figure 1: Projected Number of People with Dementia Worldwide, 2010-
2050 [22].
Figure 2: Distribution of Total Societal Costs (%) of Dementia by World 
Bank Income level [2].
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Pharmacological Approach 
Implementation of pharmacological methods is necessary when 
non-pharmacological interventions are unsuccessful or when there 
is no response to the BPSD treatment [9,23]. There are several classes 
of drugs that have been utilized for the management of BPSD. The 
categories are listed below:
Anticonvulsants
There are studies associated with the use of Carbamazepine, 
sodium valproate, and gabapentin for the treatment of behavioural 
symptoms related to patients with dementia. However, evidence 
shows that treatment with valproate was ineffective in managing 
BPSD [23,29]. Carbamazepine revealed short- term effectiveness 
for agitated behaviour [23,30]. Although gabapentin alone and 
combined with psychotropic drugs showed efficacy for the BPSD 
treatment, however further research is required [23,31-32]. On the 
basis of current data, anticonvulsant drugs are not recommended for 
the treatment of BPSD associated with dementia [23,33]. 
Cholinesterase Inhibitors (ChEIs)
At present, there is evidence accounting for the benefits of ChEIs. 
Rodda et al. [34] showed that despite limitation of effectiveness data, 
ChEIs can be used for BPSD in Alzheimer’s disease [35]. The US-FDA 
has approved donepezil, galantamine, and rivastigmine for treatment 
of symptoms of Alzheimer’s disease; however, the recommendations 
of ChEIs are inconsistent in guidelines [11]. If behavioural symptoms 
still persist during ChEIs use, alternative drug classes may be 
considered as therapeutic options [24]. 
Antidepressants 
Symptoms of depression are common in patients with dementia. 
Selective Serotonin Reuptake Inhibitors (SSRI) was observed 
for efficacy on depression [36]. Citalopram and sertraline had 
commensurate efficacy on agitated behaviour relative to risperidone 
or haloperidol. However, the guidelines around administration 
of antidepressants for behavioural disturbances are controversial, 
except when there is a co morbidity of depression [11,23,37]. 
Memantine or NMDA (N-Methyl-D-Aspartate)
The NMDA receptor antagonist (memantine) is currently the 
US-FDA approved drug for treatment of moderate to severe stages 
of Alzheimer’s disease [37]. Nevertheless, the recommendation for 
BPSD is disputed in guidelines. The SIGN guideline highlighted 
that there is insufficient evidence for using memantine for the 
management of patients with BPSD [23]. In contrast, the NICE 
guidelines recommended memantine for non-cognitive symptoms 
in moderate and severe stages and discourage use of ChEIs and 
antipsychotics [35].
Antipsychotics 
Antipsychotics are divided into two classes: typical and atypical. 
There are consistent guidelines for introducing antipsychotics for 
treatment of patients with BPSD, in particular for symptoms such 
as agitation, aggression, and psychosis [11,35]. Due to the adverse 
side effects, the NSW guidelines do not recommend conventional 
antipsychotics as a first-line drug [9]. Atypical antipsychotic drugs are 
commonly prescribed for BPSD rather than typical antipsychotics. 
Drouillard, Mitanni and Chan noted that atypical antipsychotics were 
useful for managing BPSD related to agitation and aggression [38]. 
However, patients should be investigated prior to administration of 
these medications. Aripiprazole, olanzapine, and risperidone showed 
statistically significant effects for psychosis, agitation, and global 
behavioural symptoms in dementia [39]. And thus, Tampi et al. 
recommended that risperidone, aripiprazole and olanzapine should 
be considered as the first-line treatment [12]. 
The management of BPSD should integrate both non-
pharmacological treatments and pharmacological treatments. Non-
pharmacological approaches should be introduced as initial strategies. 
When non-pharmacological interventions show no effect, starting 
medication is considered appropriate. Atypical antipsychotics are 
considered to be beneficial as first-line drugs for the treatment of 
psychotic disorders in elderly people with dementia as they improve 
symptoms without causing adverse effects. However, the use of these 
drugs is controversial due to issues around drug safety and because the 
goal of pharmacological therapy is to reduce problematic disorders 
than merely eliminate symptoms. The concept of antipsychotic drugs 
is to “start slow, go slow”. Thus, caregivers should be encouraged 
to take part in the decision-making process in patient care. Also, 
physicians should scrutinize the risks vs. benefits of pharmacological 
treatments to patients and their prescription should be considered on 
a case by case basis. 
Efficacy and Cost-effectiveness of Atypical 
Antipsychotic Drugs for Dementia
The database search for the efficacy of atypical antipsychotic 
(risperidone, olanzapine, quetiapine and aripiprazole) drugs for 
dementia retrieved 2190 articles from MEDLINE, PsycINFO, and 
the Cochrane Library. Of these, 1075 articles were retrieved from 
MEDLINE, 754 articles retrieved from PsycINFO and 361 articles 
from the Cochrane Library. The titles were screened for inclusion 
and exclusion criteria. 2063 articles were excluded from the study 
due to their title. The remaining 127 articles were identified for 
further scrutiny. A further 81 articles were excluded after screening 
their abstracts. From the remaining 46 articles a further 26 were 
excluded due to duplication. 20 articles remained to undergo the next 
step (screening for full paper). Six articles were excluded due to not 
meeting the inclusion criteria. Another paper was excluded due to 
lack of access to the full-text. 
Inclusion criteria were: 
1) Participants: people with dementia, people with 
behavioural and psychological symptoms of dementia;
2) Interventions: atypical antipsychotic, risperidone, 
olanzapine, quetiapine and aripiprazole for treatment 
of dementia, Alzheimer’s disease, behavioural and 
psychological symptoms of dementia and neuropsychiatric 
symptoms;
3) Study designs: randomized controlled trial, placebo 
controlled, double-blind, parallel-group trials comparing 
drugs with placebo; and
4) Outcomes: Behavioural Pathology in Alzheimer’s disease 
Rating Scale (BEHAVE-AD), Clinical Global Impression 
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(CGI) scale, Neuropsychiatric Inventory (NPI), Cohen-
Mansfield Agitation Inventory (CMAI), Brief Psychiatric 
Rating Scale (BPRS), Severe Impairment Battery (SIB), 
time for initial treatment to the discontinuation, and 
Mini-Mental State Examination (MMSE).
A further search for the cost-effectiveness of atypical antipsychotics 
from electronic databases was conducted in MEDLINE, the Centre for 
Reviews and Dissemination (CRD) (containing the National Health 
System Economic Database (NHS EED), the Database of Abstracts 
of Reviews of Effects (DARE), and Health Technology Assessment 
database) were searched. A total of 37 articles were retrieved. The 
titles were screened for inclusion and exclusion criteria. After 
screening the titles, 27 articles were excluded. A further seven articles 
were excluded after screening the abstracts, whilst another one was 
excluded as it was not in an English format which left two articles to 
be included in the study. 
Inclusion criteria were: 
1) Population: people with dementia,  people with  
Alzheimer’s disease;
2) Interventions: risperidone, risperdal, olanzapine, zyprexa, 
aripiprazole, abilify, quetiapine, and seroquel;
3) Study designs: comparison in terms of cost, and cost and  
health outcome, costs; and
4) Outcomes: QALYs, monetary costs, health benefits, 
health outcomes.
A systematic literature search identified only 13 clinical trial 
studies (with comparators) to demonstrate clinical effectiveness 
of atypical antipsychotics treatment of dementia with respect to 
risperidone, olanzapine, aripiprazole or quetiapine [40-52]. The 
results showed that the adverse events may offset efficacy associated 
with atypical antipsychotics for the treatment of BPSD. The serious 
side effects in senile dementia accounted for cerebrovascular events, 
extra pyramidal symptom, falls, somnolence, sedation, disinhibition, 
depression, incontinence, Parkinsonism, weight gain, orthostatic 
hypotension, dyskinesia and cognitive function impairment [46,53].
A cost-effectiveness of atypical antipsychotics retrieved only 
two quality studies [54-55]. Kirbach et al. focused on olanzapine for 
agitation and psychosis in Alzheimer’s disease, based on the Markov 
state-transition model to estimate the cost-effective treatment. The 
results showed that olanzapine was cost-effective compared with an 
untreated group, for agitation and psychosis in AD in a community 
dwelling in the United States, using the US health system perspective 
[54]. However, the limitation of this study was that the cost variables 
entered into the model were derived from other studies and health 
utilities were deduced from schizophrenia studies. Rosenheck et al. 
used the cost-benefit analysis in a randomized controlled trial of 
second-generation antipsychotics and placebo for treating psychosis, 
agitation, or aggression in AD with a 9 months follow-up period. The 
findings demonstrated that risperidone, olanzapine and quetiapine 
showed no differences in effectiveness compared to the placebo, in a 
community dwelling in the United States [55]. 
Discussion
Despite the US-FDA warning in 2005 in relation to using 
atypical antipsychotics for dementia due to increased incidence in 
cerebrovascular mortality of approximately 1.5 -1.7 times greater, the 
trend of prescribing atypical antipsychotic for patients with dementia 
has not receded. Atypical antipsychotics are significantly prescribed 
for the treatment of BPSD [56-57]. Recently, evidence showed that 
second-generation antipsychotic drugs had modest efficacy for 
the treatment of behavioural and psychological symptoms, namely 
agitation, aggression, psychosis, depression, anxiety. However, 
due to the limited and conflicting evidence for efficacy of atypical 
antipsychotic drugs their use for management of BPSD in patients 
with dementia is debatable. 
Although atypical antipsychotics can be debated on the ground 
on effectiveness and adverse events, these drugs have been widely 
used for the treatment behavioural disturbance related to geriatric 
dementia [58]. This is because the severity of behavioural disturbance 
worsens as the disease progresses. This has potential impacts on 
morbidity, caregiver’s general health, the burden of care, patients’ and 
caregivers’ distress, risk of harm to patients and caregivers, and costs 
of treatment. Consequently, it is important to weigh the risks and 
benefits when making judgments regarding the treatment and cost of 
behavioural problems in people with dementia. The pharmacological 
approaches are important and these are recommended when non-
pharmacological methods fail. Despite the modest efficacy in the 
reduction of behavioural symptoms, the potential improvement 
of the condition has a considerable impact on the quality of life of 
patients and caregivers.
There is a significant lack of pharmacoeconomic research on 
using atypical antipsychotics for the treatment of dementia. Further 
comprehensive research should be carried out into this field. We 
have found a good number of studies exploring the effectiveness and 
cost-effectiveness of atypical antipsychotics for schizophrenia using 
a decision-analytical model. However, there were only a couple of 
studies which have focused on the use of AAs for dementia and that 
too with several limitations. Therefore, it is pertinent to undertake 
further systematic and comprehensive research on the safety and 
efficacy of atypical antipsychotics for the management of BPSD. 
This is essential in improving clinical practice and suggesting better 
pathways for dementia treatment as well as in mitigating the adverse 
impacts on the quality of life of patients and their caregivers.
1Atypical antipsychotics are also called second-generation 
antipsychotics, or narcoleptic drugs such as clozapine, amisulpride, 
aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, and 
risperidone.
2Typical antipsychotics are also known as conventional, classical or 
first-generation antipsychotics such as chlorpromazine, haloperidol, 
flupentixol, prochlorperazine, sulpiride and trifluoperazine.
(https://www.gov.uk/government/organisations/medicines-and-
healthcare-products-regulatory-agency)
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